These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 15055565

  • 1. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
    Vogelson CT, Abelson MB, Pasquine T, Stephens DM, Gamache DA, Gross RD, Robertson SM, Yanni JM.
    Allergy Asthma Proc; 2004; 25(1):69-75. PubMed ID: 15055565
    [Abstract] [Full Text] [Related]

  • 2. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
    Spangler DL, Abelson MB, Ober A, Gotnes PJ.
    Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
    [Abstract] [Full Text] [Related]

  • 3. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
    Greiner JV, Udell IJ.
    Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
    [Abstract] [Full Text] [Related]

  • 4. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
    Abelson MB, Spitalny L.
    Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
    Lanier BQ, Finegold I, D'Arienzo P, Granet D, Epstein AB, Ledgerwood GL.
    Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.
    Lanier BQ, Abelson MB, Berger WE, Granet DB, D'Arienzo PA, Spangler DL, Kägi MK.
    Clin Ther; 2002 Jul; 24(7):1161-74. PubMed ID: 12182260
    [Abstract] [Full Text] [Related]

  • 8. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model.
    Abelson MB, Welch DL.
    Acta Ophthalmol Scand Suppl; 2000 Jul; (230):60-3. PubMed ID: 11057354
    [Abstract] [Full Text] [Related]

  • 9. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB, Greiner JV.
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
    Abelson MB, Lanier RQ.
    Acta Ophthalmol Scand Suppl; 1999 Dec; (228):53-6. PubMed ID: 10337434
    [Abstract] [Full Text] [Related]

  • 12. Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability.
    Beauregard C, Stephens D, Roberts L, Gamache D, Yanni J.
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):315-20. PubMed ID: 17803429
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H, Ohashi Y, Takamura E.
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
    Spangler DL, Bensch G, Berdy GJ.
    Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
    [Abstract] [Full Text] [Related]

  • 15. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model.
    Deschenes J, Discepola M, Abelson M.
    Acta Ophthalmol Scand Suppl; 1999 Aug; (228):47-52. PubMed ID: 10337433
    [Abstract] [Full Text] [Related]

  • 16. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
    Leonardi A, Abelson MB.
    Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
    Abelson MB, Spangler DL, Epstein AB, Mah FS, Crampton HJ.
    Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
    Avunduk AM, Tekelioglu Y, Turk A, Akyol N.
    Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.
    Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A.
    Jpn J Pharmacol; 2002 Apr; 88(4):379-97. PubMed ID: 12046981
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model.
    Abelson MB.
    Ann Allergy Asthma Immunol; 1998 Sep; 81(3):211-8. PubMed ID: 9759796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.